Mirum Pharmaceuticals provided preliminary and unaudited estimates for full-year 2025 net product sales, year-end cash balance, corporate updates, and full-year 2026 outlook.
The company reported successful commercial growth, advanced clinical programs, and plans for pipeline expansion through acquisitions.
Mirum Pharmaceuticals emphasized its financial strength, commitment to patients, and upcoming clinical catalysts for 2026.
Mirum Pharmaceuticals, a pharmaceutical firm focused on rare diseases, delivered a robust performance in 2025, showcasing impressive commercial growth and strategic pipeline advancements. The company's proactive approach to acquisitions and clinical development positions it for sustained success in 2026 and beyond.
2025 Net Product Sales
In 2025, Mirum Pharmaceuticals achieved approximately $520 million in net product sales, surpassing the upper end of its guidance range.
2026 Sales Outlook
Mirum Pharmaceuticals anticipates global net product sales between $630 million and $650 million for 2026, indicating a significant growth trajectory.
Pipeline Advancements
Key clinical studies for Volixibat VISTAS and LIVMARLI EXPAND are progressing well, with anticipated positive outcomes, underscoring the company's commitment to innovation and therapeutic advancements.
Acquisition Update
Mirum Pharmaceuticals plans to acquire Bluejay Therapeutics, augmenting its pipeline with brelovitug to address chronic hepatitis delta virus (HDV), consolidating its position in the rare disease segment.
Financial Strength
Mirum Pharmaceuticals reported a positive cash flow from operations in 2025, projecting a year-end cash and investment balance of approximately $392 million, bolstering its financial stability for future strategic initiatives.
- Mirum's exceptional performance in 2025 reflects the scalability of its rare disease business model and the successful expansion of its global commercial presence, reinforcing investor confidence in the company's growth prospects.
- The company's strategic focus on advancing late-stage clinical programs and expanding its pipeline through targeted acquisitions demonstrates a clear commitment to enhancing long-term shareholder value and fostering innovation in rare disease treatments.
- With pivotal clinical catalysts on the horizon for 2026, Mirum Pharmaceuticals is well-equipped to sustain its operational momentum, drive further growth, and deliver value to its stakeholders, solidifying its position as a key player in the pharmaceutical landscape.
Mirum Pharmaceuticals' preliminary unaudited 2025 results underscore a year marked by substantial achievements in commercial expansion and pipeline progression. The company's proactive strategic initiatives and strong financial performance lay a robust foundation for continued success in 2026 and beyond, positioning Mirum as a formidable force in the pharmaceutical sector.